QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:MRTX

Mirati Therapeutics Stock Forecast, Price & News

$191.33
+0.75 (+0.39 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$187.90
Now: $191.33
$198.52
50-Day Range
$181.00
MA: $203.95
$216.32
52-Week Range
$66.01
Now: $191.33
$249.42
Volume496,533 shs
Average Volume444,719 shs
Market Capitalization$9.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.64
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Mirati Therapeutics logo

Headlines

MRTX Mar 2021 195.000 call
March 7, 2021 |  au.finance.yahoo.com
Why Turning Point Is Turning Heads
February 23, 2021 |  msn.com
MRTX Jan 2022 40.000 call
January 9, 2021 |  au.finance.yahoo.com
Mirati Therapeutics: A Gift That Keeps On Giving
December 31, 2020 |  seekingalpha.com
Is MRTX A Good Stock To Buy According To Hedge Funds?
December 24, 2020 |  finance.yahoo.com
Notable Tuesday Option Activity: MRTX, DE, SQ
December 15, 2020 |  nasdaq.com
Mirati Therapeutics EPS beats by $0.07
November 4, 2020 |  seekingalpha.com
MRTX Jan 2021 90.000 put
November 2, 2020 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410
Employees111
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.34 million
Book Value$9.67 per share

Profitability

Net Income$-213,260,000.00

Miscellaneous

Market Cap$9.69 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

393rd out of 1,971 stocks

Pharmaceutical Preparations Industry

192nd out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$191.33
+0.75 (+0.39 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

Is Mirati Therapeutics a buy right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Mirati Therapeutics stock.
View analyst ratings for Mirati Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Mirati Therapeutics?

Wall Street analysts have given Mirati Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mirati Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Mirati Therapeutics
.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) issued its earnings results on Thursday, February, 25th. The biotechnology company reported ($2.08) earnings per share for the quarter, beating the consensus estimate of ($2.23) by $0.15.
View Mirati Therapeutics' earnings history
.

How has Mirati Therapeutics' stock been impacted by Coronavirus?

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRTX stock has increased by 147.3% and is now trading at $191.33.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MRTX?

16 Wall Street analysts have issued 1 year target prices for Mirati Therapeutics' stock. Their forecasts range from $116.00 to $285.00. On average, they anticipate Mirati Therapeutics' share price to reach $218.57 in the next year. This suggests a possible upside of 14.2% from the stock's current price.
View analysts' price targets for Mirati Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the following people:
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 63, Pay $1.01M)
  • Dr. James G. Christensen, Chief Scientific Officer (Age 53, Pay $655k)
  • Mr. Daniel R. Faga, COO & Principal Financial Officer (Age 41)
  • Ms. Vickie S. Reed, Sr. VP of Technical Operation & Chief Accounting Officer (Age 59)
  • Temre Johnson, Director of Investor Relations & Corp. Communications
  • Ms. Reena R. Desai, VP, Gen. Counsel & Corp. Sec.
  • Dr. Matthew Marx Ph.D., Sr. VP & Head of Drug Discovery
  • Mr. Philip Roberts, Sr. VP of Technical Operations
  • Mr. Benjamin J. Hickey, Chief Commercial Officer (Age 45)
  • Dr. Kelly Covello Ph.D., VP & Head of Medical Affairs

Who are some of Mirati Therapeutics' key competitors?

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Square (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (9.02%), BlackRock Inc. (8.51%), Price T Rowe Associates Inc. MD (3.10%), Janus Henderson Group PLC (2.29%), Orbimed Advisors LLC (2.28%) and Lord Abbett & CO. LLC (1.51%). Company insiders that own Mirati Therapeutics stock include Avoro Capital Advisors Llc, Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Isan Chen, Jamie A Donadio, Ltd Braslyn, Maria E Martinez, Michael G Grey, Venbio Select Advisor Llc and Vickie S Reed.
View institutional ownership trends for Mirati Therapeutics
.

Which major investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Janus Henderson Group PLC, Orbimed Advisors LLC, Amundi Pioneer Asset Management Inc., UBS Asset Management Americas Inc., Assenagon Asset Management S.A., Emerald Advisers LLC, and Emerald Mutual Fund Advisers Trust. Company insiders that have sold Mirati Therapeutics company stock in the last year include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Isan Chen, Ltd Braslyn, Maria E Martinez, and Vickie S Reed.
View insider buying and selling activity for Mirati Therapeutics
or view top insider-selling stocks.

Which major investors are buying Mirati Therapeutics stock?

MRTX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Norges Bank, Lord Abbett & CO. LLC, Darwin Global Management Ltd., Price T Rowe Associates Inc. MD, Avoro Capital Advisors LLC, Morgan Stanley, and Renaissance Technologies LLC.
View insider buying and selling activity for Mirati Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $191.33.

How much money does Mirati Therapeutics make?

Mirati Therapeutics has a market capitalization of $9.69 billion and generates $3.34 million in revenue each year. The biotechnology company earns $-213,260,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

Mirati Therapeutics employs 111 workers across the globe.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is www.mirati.com.

Where are Mirati Therapeutics' headquarters?

Mirati Therapeutics is headquartered at 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.